Clinical Trial: Drug that Stops Myeloma Progression with Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma


TGF-β, a multifunctional cytokine, is produced in multiple myeloma cells and cells in the bone marrow environment and stimulates myeloma progression. A new drug called  TEW-797 targets this cytokine and kills myeloma cells alone and with other myeloma drugs.

“Our data demonstrate that TEW-7197 effectively modulates the MM TME and is associated with a potent anti-myeloma effect in an immunocompetent murine model of MM,” lead author Byung-gyu Kim, DVM, of Case Western Reserve University in Cleveland, Ohio, said during his presentation of the results of a study using this drug with ixazomib.


TEW-7197 is now in a clinical trial with pomalidomide for relapse/refractory myeloma patients.

The trial is open at two sites in Ohio. To learn more about this clinical trial, click here:

Pomalidomide and TEW-7197 Clinical Trial

About Author

MyelomaCrowd Editorial Contributor. Studying Nursing. Daughter to a parent with cancer.

Leave A Reply

Please enter the correct captcha code to verify that you are human.